logo
Plus   Neg
Share
Email

Alexion Pharma Raises 2019 Outlook

Alexion Pharmaceuticals Inc. (ALXN) increased its revenues and earnings per share guidance for fiscal year 2019.

The company raised its fiscal year 2019 earnings per share outlook to a range of $8.58 to $8.78 from the prior estimation of $8.13 to $8.41 per share. It also increased its non-GAAP earnings per share guidance to a range of $10.25 to $10.40 from the previous outlook of $9.65 to $9.85 per share. Analysts polled by Thomson Reuters expect the company to report earnings of $9.94 per share for fiscal year 2019. Analysts' estimates typically exclude special items.

The company now projects total revenues for fiscal year 2019 to be $4.860 billion to $4.890 billion, compared to the prior outlook of $4.750 billion to $4.800 billion. Analysts expect revenues of $4.85 billion.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients. Ferring Pharmaceuticals US is recalling various nasal sprays citing superpotency or amounts of desmopressin higher than specified, the U.S. Food and Drug Administration announced in a statement. The recall involves all lots on the market of DDAVP Nasal Spray 10 mcg/0.1mL, Desmopressin Acetate Nasal Spray 10 mcg/0.1mL, and STIMATE Nasal Spray 1.5 mg/mL. U.S. President Donald Trump has issued executive orders to ban Chinese mobile application TikTok as well as WeChat, citing a threat to national security and its economy. China's ByteDance Ltd. owns TikTok, a video-sharing mobile app, while Tencent Holdings Ltd. owns WeChat, a messaging, social media, and electronic payment app.
Follow RTT